{"filing":{"accession_number":"0001193125-26-269431","cik":"0001817229","ticker":"VOR","company_name":"Vor Biopharma Inc.","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"vor-20260611.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1817229/000119312526269431/vor-20260611.htm"},"events":[{"id":10796,"run_id":9472,"accession_number":"0001193125-26-269431","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder voting results from Vor Biopharma's Annual Meeting held on June 12, 2026. The filing reports final voting tallies for three proposals: election of two Class II directors (Andrew Levin and Fouad Namouni), approval of an amended 2021 Equity Incentive Plan, and ratification of Ernst \u0026 Young LLP as independent auditor. The detailed vote counts for each proposal are the core content of Item 5.07, which is the standard Item for reporting shareholder meeting results.","company_name":"Vor Biopharma Inc.","ticker":"VOR","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":7200,"accession_number":"0001193125-26-269431","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Vor Biopharma's Annual Meeting held on June 12, 2026. The filing reports final voting tallies for three proposals: election of two Class II directors (Andrew Levin and Fouad Namouni), approval of an amended 2021 Equity Incentive Plan, and ratification of Ernst \u0026 Young LLP as independent auditor. The detailed vote counts for each proposal are the core content of Item 5.07, which is the standard Item for reporting shareholder meeting results.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:18:21.639747+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7200,"accession_number":"0001193125-26-269431","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Vor Biopharma's Annual Meeting held on June 12, 2026. The filing reports final voting tallies for three proposals: election of two Class II directors (Andrew Levin and Fouad Namouni), approval of an amended 2021 Equity Incentive Plan, and ratification of Ernst \u0026 Young LLP as independent auditor. The detailed vote counts for each proposal are the core content of Item 5.07, which is the standard Item for reporting shareholder meeting results.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:18:21.639747+00:00","company_name":"Vor Biopharma Inc.","ticker":"VOR","filing_date":"2026-06-12"}]}